Icon
+91 94997 68112
Login Register

Hetlioz LQ - (4 mg/mL ; Suspension)

Tasimelteon Vanda pharma
4 mg/mL ; Suspension
Less Than $1000 mn
None None
None None
None None
HETLIOZ is a melatonin receptor agonist. HETLIOZ LQ oral suspension is indicated for the treatment of: • Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age.
Yes
Hetlioz LQ Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23 Patent 24
******* *******
  1. *** *, **** : * **** ** ** ***** *** ***** ** *** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.